We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Mercia Asset Management Plc | LSE:MERC | London | Ordinary Share | GB00BSL71W47 | ORD 0.001P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 29.50 | 29.00 | 30.00 | 29.50 | 29.50 | 29.50 | 106,078 | 07:32:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 25.88M | 2.84M | - | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
30/4/2020 11:35 | The fact that they have a stake in Abingdon Health is important I feel.Having a number of portfolio investments all working together on delivering a rapid diagnostic tool and associated services are all very value added.I feel the smart money is already recognising this. Only a matter of time until the pack catch up. | longshanks | |
30/4/2020 10:45 | I am indebted to you Mr Railway for a very interesting write-up the other day (#591), leading me to look at Omega and other companies involved in testing (the unlisted Mologic website is informative) and components (EFK) and generally getting a feel for this space when I really only knew Roche before. Now another very useful tip on Research Tree on which I have re-registered. And I haven't read the Oxgene write-up as yet. I am interested in PE/VC valuations now, in general am guessing that discounts to pre pandemic publihed NAV of around 25-30% may be appropriate with a few start-ups likely to go under.In general valuations need to be much more conservative. I have been in this one for a few years after talking with the principals and liking the direct/managed investment style and the geographical bias though I was concerned that some of the managed funds would naturally decrease with the demise of Woodford's funds. I decided to stay in, even after being miffed at the heavily discounted institutional placement, as the discount to my very roughly adjusted NAV seemed extreme and the cash position sound. And of course AUM has nearly doubled with the acquisition and the recent Northern fund raise. | srichardson8 | |
30/4/2020 05:56 | You can find plenty of info on Research Tree. They've got a two month free offer on their full service because of covid. A kind gesture. | gwr7 | |
29/4/2020 23:20 | I haven't had a chance to look in depth, but I like the breadth of the investment portfolio. I have taken an initial position with a view to buying more as I get to know the business. | longshanks | |
29/4/2020 20:23 | Nice one longshanks. You did your homework then. I did some speed reading after joining the dots on twitter. At first I was disappointed with NAC being private, but the more I read about MERC the more I felt it was my sort of investment. Oxgene is another player on our side. | gwr7 | |
29/4/2020 17:38 | Managed to pick up a fair number today. Has to pay a little more than I wanted but not too much more. | longshanks | |
29/4/2020 13:25 | Heavily oversold here, more upside to come. | its the oxman | |
29/4/2020 11:37 | Only way to buy is F&K and at the full ask,,,,,,MMs really need to open the market and let the buyers in ! Happy to have got some more this morning | cheshire man | |
29/4/2020 10:11 | Thanks GWR, interesting article. | andyview | |
29/4/2020 09:52 | This article gives an excellent summary of antibody tests for covid. The work The Native Antigen Company is involved in is towards the end but the whole article is worth a read. | gwr7 | |
29/4/2020 09:38 | ;-)) no trade again to buy... | andyview | |
29/4/2020 09:37 | The other reason I bought in is that I have a 1990 300SE and I like the ticker : ) | gwr7 | |
29/4/2020 09:18 | Hopefully, word getting out and confidences returning simultaneously Much more to come from MERC imv, | mr.oz | |
29/4/2020 09:12 | More buying again this morning pushing the price up. Oversold and great exposure to covid focussed companies should see this rerate imho. gla | andyview | |
29/4/2020 07:59 | Great post from gwr, thanks | andyview | |
28/4/2020 20:26 | Thanks for the heads up, railway man.Looks very interesting. | longshanks | |
28/4/2020 18:07 | The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines. About The Native Antigen Company Founded in 2010, The Native Antigen Company has rapidly become one of the world’s leading suppliers of reagents for infectious disease. Over the last 10 years, the Native Antigen Company has developed rapid response manufacturing capabilities to produce reagents for emerging epidemic diseases, guided by the World Health Organisation’s R&D Blueprint, which outlines the accelerated development of vaccines and increased availability of accurate and reliable diagnostics for priority emerging infectious diseases. The Native Antigen Company’s proprietary mammalian, VirtuE expression system from which these reagents have been expressed, is able to introduce proper protein folding and post-translational modifications to recombinant proteins, which are essential for full biological and antigenic activity. The company is widely known for its expertise in this field, having used its VirtuE expression system to rapidly develop antigens for other major health threats, including the recent Zika and Dengue outbreaks. | cheshire man | |
28/4/2020 17:51 | I bought some today. I used a fill or kill order. Mercia has numerous promising companies within and without the covid space. I like the way they pick them. Most of the admin costs are covered by the profitable asset management business and they are a lead investment manager for the government’s northern powerhouse initiative. I believe the drive to support quality businesses oop north has legs. Add to that the share price was beaten down by forced sales from Woodford and Invesco funds, and is at a big discount to NAV limiting downside. It looks like a good investment to me. It is definitely long term so it is not going to multi-bag in weeks like other shooting stars of the minute but I believe it will do in time. One of the reasons Woodford failed was that Hargreaves Lansdown were using their promotional fund rankings to funnell investors into his funds who weren’t suited to them. Woodford was the goose that laid the golden egg but that was with high quality income companies. HL turned a blind eye to the investments making up his funds after he set up on his own, and also their open-ended nature. When PIs wanted to withdraw money en masse there wasn’t the liquidity in the smaller companies Woodford had invested in. Redemptions couldn’t be covered without disastrous forced sales. I think Mercia was a good pick by him. Obviously the Mercia share price performance has been poor since launch and that has upset investors. Also they shunned PIs in a discounted placing last year at 25p which forced an apology in the FT so hopefully they learnt from that. Mercia’s investments in companies take time to realise their true value and they need some high profile company sales or IPOs to cement their reputation. I think they’ll achieve them. As ever DYOR. | gwr7 | |
28/4/2020 15:16 | No trade to buy at the mo | andyview | |
28/4/2020 14:42 | Fwi, I am sure we have not heard the last of the collaboration regarding the large-scale production of high-quality COVID-19 antigens, which is a critical step toward the development of diagnostics and vaccines. | wan | |
28/4/2020 14:18 | Thanks for the response and I agree there are more targeted companies available however I like the spread of investments here which increases exposure and for me potential of success. I notice the volume has ticked up considerably today with some juicy buys I would suggest. As you rightly point out, mercias got much many other attractive investments- a compelling investment opportunity imho. Gla | andyview | |
27/4/2020 20:13 | I suppose it’s an angle. The issues for me would be that it’s a dilute way of getting involved in the covid story (they have direct investments in numerous unrelated companies) and you would have no control over your covid exit strategy. I think there is still value to be had in pure plays if you’re selective. I should add I'm a holder here for other reasons than hoping it will be a 'hot' covid stock. | columbarius | |
27/4/2020 09:47 | Considering the investments that this company has and the resulting exposure to the companies involved with covid solutions, it seems to be under the radar at the moment. Is that a fair assessment? gla | andyview | |
27/4/2020 09:33 | i've been adding a few of these and topped up with a few more this morning. looks promising gla | andyview | |
27/4/2020 07:50 | foreverfalling...... | cheshire man |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions